OriA631-B / Oricell - LARVOL DELTA

Enhanced GPC3-chimeric antigen receptor T cells with secreted bi-specific CD39-PD-L1 antibody for improved liver cancer therapy (AACR 2025) - "We previously demonstrated that a bi-specific antibody, OriA631-B, which targets CD39—an enzyme crucial for converting extracellular ATP into adenosine—and PD-L1, yields significant antitumor effects. In a mouse model of liver cancer, GPC3 CAR-T-CD39-VHH-PD-L1-ScFv exhibited superior antitumor activity compared to GPC3 CAR T cells alone. Specifically, while GPC3 CAR T cells inhibited tumor growth, the GPC3 CAR-T-CD39-VHH-PD-L1-ScFv nearly eliminated tumors by day 20, whereas tumors in the GPC3 CAR T group measured around 200 mm³.This enhanced efficacy is attributed to the localized delivery of the bi-specific antibody fragment, which effectively inhibits adenosine signaling and PD-L1-mediated immune checkpoint blockade.Our findings suggest that GPC3 CAR-T-CD39-VHH-PD-L1-ScFv represents a novel therapeutic strategy for liver cancer, offering improved efficacy and potentially reduced side effects associated with systemic antibody administration."

Bispecific • CAR T-Cell Therapy • IO biomarker • Liver Cancer • Oncology • Solid Tumor • ENTPD1 • GPC3

A novel bi-specific antibody targeting CD39 and PD-L1 for enhanced cancer immunotherapy (AACR 2025) - "This study introduces OriA631-B, a pioneering bi-specific antibody designed to simultaneously engage CD39 and PD-L1. By concurrently targeting CD39-mediated immune suppression and PD-L1-mediated T cell exhaustion, this bi-specific antibody may circumvent resistance mechanisms and enhance T cell engagement with tumor cells, ultimately improving patient outcomes. Further clinical evaluation is warranted to fully assess the therapeutic potential of this innovative bi-specific antibody in cancer immunotherapy."

Bispecific • Oncology • ENTPD1